Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GASTRICHIP: D2 resection with or without HIPEC in locally advanced gastric carcinoma
2024-516358-23-00Phase 3Completed
- Sponsor
- Hospices Civils de Lyon
- Start
- Aug 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of oxaliplatin, fluorouracil and levoleucovorin in gastric adenocarcinoma (2 arms), sponsored by Hospices Civils de Lyon. Primary endpoint: Overall survival. Started Aug 2024; status: completed.
02
Drugs
oxaliplatinfluorouracillevoleucovorin
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on 2024-516358-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516358-23-00.